Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
TUMOUR-HOST INTERACTIONS IN LIVER CANCER OF CHILDHOOD AND ADULTS (THRIVE)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Mission
Theme: Cancer
Destination: Cancer
Action type: Research and Innovation actions
Countries involved: Spain,Germany,France,Belgium,Switzerland,United Kingdom,Israel,Italy,Netherlands
Call: Addressing poorly-understood tumour-host interactions to enhance immune system-centred treatment and care interventions in childhood, adolescent, adult and elderly cancer patients. (HORIZON-MISS-2023-CANCER-01, 2023)
Start date: 2023-12-01
End date: 2028-11-30
Duration (months): 60.0
Total project cost (EUR): 10396703.0
EU funding (EUR): 10396703.0
Participants: 13
Project status: SIGNED

Liver cancer is a major health problem with ~1 million cases diagnosed each year (~90,000 cases/year in Europe), and it is the 3rd cause of cancer-related mortality worldwide. Hepatocellular carcinoma (HCC) in adults, and hepatoblastoma (HB) in children are considered poorly understood cancers. HCC is a difficult-to-cure cancer (curation rate ~ 30%) with poor outcome (median survival < 2 years in advanced stages), due to limited understanding of at-risk populations, resistance to therapies and lack of precision oncology. In HB, outcomes are hampered in one fourth of cases due disease progression after surgical intervention and adjuvant chemotherapy. THRIVE aims by to improve the outcome of both paediatric and adult liver cancer patients by understanding at-risk populations, tumour-host interactions, and by developing biomarkers for current therapies and novel, affordable treatments to overcome resistance. THRIVE brings together a strong, multidisciplinary team -13 partners, from 8 countries- with complementary expertise to leverage cutting-edge technologies (single-cell RNASeq, spatial transcriptomics, microbiota analysis, artificial intelligence, mouse models and patient-derived organoids) and sectors (i.e academia, SMEs, hospitals, patient associations) and 15 patient cohorts (~6,700 samples). THRIVE expects to: 1) Define molecular features of cancer predisposition and at-risk populations for development of liver cancer. 2) Develop a complete human liver cancer blueprint of tumour, immune, stromal cells and intra-tumoral microbiomes. 3) Identify AI-based and molecular markers of response to treatments. 4) Implement a preclinical drug testing platform for discovery of affordable therapies with high social impact. 5) Maximize the impact in the European society by integrating SSH disciplines, delivering accessible and re-usable data and tools to support EU initiatives such as the UNCAN.eu platform, and by influencing policymakers and health professionals. This action is part of the Cancer Mission cluster of projects on “Understanding (tumour-host interactions)".

Keywords: liver cancer,hepatocellular carcinoma,hepatoblastoma,tumour host interaction,single cell sequencing,at risk populations,artificial intelligence,microbiome,immunotherapy,organoids,uncan
Merging scientific Evidence with Regulatory practices and Leveraging identification Of endocrine disruptors using New approach methodologies (MERLON)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Health
Theme: Health
Destination: Living and working in a health promoting environment
Action type: Research and Innovation actions
Countries involved: Denmark,Netherlands,Sweden,France,Belgium,Spain,Norway,Estonia
Call: Health impacts of endocrine-disrupting chemicals: bridging science-policy gaps by addressing persistent scientific uncertainties (HORIZON-HLTH-2023-ENVHLTH-02, 2023)
Start date: 2024-01-01
End date: 2028-12-31
Duration (months): 60.0
Total project cost (EUR): 7587975.0
EU funding (EUR): 7587974.0
Participants: 12
Project status: SIGNED

Endocrine disrupting chemicals (EDCs) are substances that alter the function of the endocrine system and negatively affect human and animal health. In recent decades, there has been a significant increase in, for example, reproductive disorders and gender incongruence, along with a decline in fertility rates, all of which may be linked to EDC exposure. The EU has highlighted EDCs as substances of high concern and aims to minimise exposure of humans and the environment by improving regulation and policy. Yet there remain important gaps in our understanding of the impact of exposures at critical life stages and the tools for identification and ultimately regulation of EDCs. The MERLON project addresses these gaps, bringing together world-leading experts in endocrinology, chemical safety assessment, developmental and molecular biology, epidemiology, toxicogenomics, toxicokinetics modelling, regulatory toxicology, psychology, psychiatry and research ethics. We will investigate EDC-mediated effects on sexual development, providing human data on the role of EDC exposure during fetal development and changes in mini-puberty, connecting to puberty, reproductive function, and gender incongruence using existing biobanks and cohorts. MERLON will apply and develop 3R-compliant New Approach Methodologies (NAMs) focusing on sexual development and function and the effects of EDCs thereon. Our cutting-edge approaches incorporate transcriptomics, pharmacokinetic models, biomarker identification and the use of Adverse Outcome Pathways, which we will utilize to develop a roadmap for EDC identification, making the best use of NAMs into the future. With MERLON, we will engage EU risk assessment bodies, public health authorities, regulators, scientists and researchers, healthcare providers and citizens. This will ensure all relevant stakeholders have the evidence they need to minimize EDC exposure and support effective and evidence-based regulations and policies.

Keywords: reproduction,gender,endocrine disruptors,gender incongruence,nams,development,dohad,chemical regulation,aop
Rites of Passage and Monastic Communities in the late-antique Mediterranean (RITPASS)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Social Sciences and Humanities
Countries involved: Germany
Call: MSCA Postdoctoral Fellowships 2021 (HORIZON-MSCA-2021-PF-01, 2021)
Start date: 2023-09-01
End date: 2025-08-31
Duration (months): 24.0
Total project cost (EUR): 173847.36
EU funding (EUR): 173847.36
Participants: 1
Project status: SIGNED

How did medieval monastic leaders assert control over their communities? This project proposes an innovative way to approach to this often-considered question: through the rites of passage into ascetic groups in Late Antiquity (fourth-seventh centuries CE). Late-antique sources emphasise five membership rituals as particularly significant: rigorous testing; ceremonial cleansing; the offering of stability pledges; the renunciation of possessions; and the donning of uniform attire. These rites were meant to bind novices to their new lives, efface their prior identities, and enforce obligation to their abbots and abbesses. Although the scholarship on medieval monasticism is extensive, the relationship between ascetic authority structures and the aforementioned five ceremonies has received little recent substantial attention. This project proposes to investigate this relationship from the first appearance of monastic groups in the fourth century to their widespread multiplication across the Mediterranean by the seventh century. To do so, I will focus on laws, monastic rules, church canons, hagiographies, and provincial documents, five types of source which are not often brought together but represent contemporary attempts to assert control over ascetic rites of passage. My research will use a comparative, interdisciplinary framework of diachronic, transcultural and -regional, and socio-historical analysis to achieve the project’s three core goals: 1) to explore how and why these ceremonies changed; 2) to analyse how these rites supported or challenged late-antique discourses about monastic obligations and identities; and 3) to investigate how these rituals were related to other analogous rituals and processes. Furthermore, this project will contribute to the increasing scholarly interest in medieval monastic perspectives beyond the Benedictine and also pave the way for epistemological reconsiderations of authority, identity, and obligation, even into the modern day.

Keywords: male and female monastic communities abbots and abbesses rituals and ceremonies obligation authority and power
Bacteriocins from interbacterial warfare as antibiotic alternative (BACtheWINNER)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: Biotechnology and Biosystems E ngineering
Panel description: Biotechnology using all organisms , biotechnology for environment  and food applications, applied plant and animal sciences , bioengineering and synthetic biology , biomass and biofuels , biohazards
Countries involved: Ireland
Call: ERC ADVANCED GRANTS (ERC-2021-ADG, 2021)
Start date: 2023-04-01
End date: 2028-03-31
Duration (months): 60.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 2
Project status: SIGNED

Antimicrobial resistance (AMR) is an ongoing global crisis exacerbated by lack of discovery of novel antimicrobials and absence of investment/innovation in pipelines by the pharmaceutical industry. New alternatives that are target-specific and do not cause collateral damage to the microbiome would revolutionise human and animal health. Bacteriocins are small antibacterial peptides produced by bacteria that are gene-encoded and can be narrow or broad spectrum. They have potential for development of new antimicrobial molecules through discovery and protein engineering resulting in potent, targeted antimicrobials. They have many possible applications including treatment of gut and topical infections, and microbiome editing. However, basic research issues stand in the way of their exploitation including low production levels often in unsuitable hosts, resistance development in bacterial targets, and inadequate potency/inhibition spectrum. The main aim of BACtheWINNER is to develop bacteriocins as novel antimicrobials by solving these challenges through combining and innovating state-of-the-art technologies in peptide bioengineering and molecular genetics, which will lay the foundation for the generation of this new family of therapeutics that target WHO and CDC priority pathogens and undesirable microbiota. To achieve this, a four-phase bacteriocin discovery and development pipeline will be implemented which takes new and existing bacteriocins and improves them through bioengineering, develops optimal combinations, (over-)produces them in desirable hosts, and validates their use in preclinical models of human infection and disease. This will pave the way for their development as precision microbiome tools and antimicrobials against AMR pathogens. We bring together unique expertise necessary to deliver this project by combining bacteriocin and microbiome research with genetic manipulation of food and gut bacteria.

Keywords: bacteriocin,microbiome,bioengineering,
Psych-STRATA - A Stratified Treatment Algorithm in Psychiatry: A program on stratified pharmacogenomics in severe mental illness (Psych-STRATA)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Health
Theme: Health
Destination: Staying Healthy in a rapidly changing society
Action type: Research and Innovation actions
Countries involved: Germany,Netherlands,Belgium,Spain,Italy,Denmark,Switzerland,Australia,United Kingdom,Norway,Sweden,France,Greece,Cyprus
Call: Towards a molecular and neurobiological understanding of mental health and mental illness for the benefit of citizens and patients (HORIZON-HLTH-2021-STAYHLTH-01, 2021)
Start date: 2022-10-01
End date: 2027-09-30
Duration (months): 60.0
Total project cost (EUR): 10276440.0
EU funding (EUR): 10276440.0
Participants: 31
Project status: SIGNED

A key problem in Mental Health is that up to one third of patients suffering from major mental disorders develop resistance against drug therapy. However, patients showing early signs of treatment resistance (TR) do not receive adequate early intensive pharmacological treatment but instead they undergo a stepwise trial-and-error treatment approach. This situation originates from three major knowledge and translation gaps: i.) we lack effective methods to identify individuals at risk for TR early in the disease process, ii.) we lack effective, personalized treatment strategies grounded in insights into the biological basis of TR, and iii.) we lack efficient processes to translate scientific insights about TR into clinical practice, primary care and treatment guidelines. It is the central goal of PSYCH-STRATA to bridge these gaps and pave the way for a shift towards a treatment decision-making process tailored for the individual at risk for TR. To that end, we aim to establish evidence-based criteria to make decisions of early intense treatment in individuals at risk for TR across the major psychiatric disorders of schizophrenia, bipolar disorder and major depression. PSYCH-STRATA will i.) dissect the biological basis of TR and establish criteria to enable early detection of individuals at risk for TR based on the integrated analysis of an unprecedented collection of genetic, biological, digital mental health, and clinical data. ii.) Moreover, we will determine effective treatment strategies of individuals at risk for TR early in the treatment process, based on pan-European clinical trials in SCZ, BD and MDD. These efforts will enable the establishment of novel multimodal machine learning models to predict TR risk and treatment response. Lastly, iii.) we will enable the translation of these findings into clinical practice by prototyping the integration of personalized treatment decision support and patient-oriented decision-making mental health boards.

Keywords: treatment resistance schizophrenia major depressive disorder bipolar disorder prediction pharmacogenomics early detection early treatment clinical trial shared decision making decision suppo
Relaxation to equilibrium for a disordered particle system (PARTYMIX)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Mathematics
Countries involved: Italy
Call: MSCA Postdoctoral Fellowships 2024 (HORIZON-MSCA-2024-PF-01, 2024)
Start date: 2026-07-06
End date: 2027-09-05
Duration (months): 14.0
Total project cost (EUR): 122198.58
EU funding (EUR): 122198.58
Participants: 1
Project status: SIGNED

A fundamental result in probability theory states that the distribution of an irreducible, time continuous Markov chain on a finite state space converges to an equilibrium as time tends to infinity. The study of Markov chain mixing time is a branch of Probability Theory that tries to understand the characteristic of this convergence and answer questions such as: How much time is needed to converge to equilibrium? Is the convergence regular or abrupt? Within this field only little effort have been made to understand how random inhomogeneities can affect the pattern of convergence to equilibrium. The objective of our research project is to develop the mathematical understanding of relaxation to equilibrium of disordered systems. To do so, we will explore in depth the case of a specific disordered model - the Simple Exclusion Process (SEP) in a random environment - with the hindsight of developing robust methods which contribute to the understanding of disordered Markov processes. Our project defines a handful of precise scientific questions on which our efforts should be focused. These concern the asymptotic behavior, as the system size go to infinity, of the spectral gap and of the mixing time for disordered Simple Exclusion Process on one dimensional graphs as well as the possible occurrence of the cutoff phenomenon for the process.

Keywords: mixing time,spectral gap,random environment,simple exclusion process,cutoff
Resolving brain cell-types with non-invasive imaging (CellPrism)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Physical and Analytical Chemical Sciences
Panel description: Analytical chemistry, chemical theory, physical chemistry/chemical physics
Countries involved: France
Call: ERC STARTING GRANTS (ERC-2024-STG, 2024)
Start date: 2025-07-01
End date: 2030-06-30
Duration (months): 60.0
Total project cost (EUR): 1587287.0
EU funding (EUR): 1587287.0
Participants: 1
Project status: SIGNED

The brain is plastic: it constantly adapts to its environment thanks to numerous cell-types with varied functions. Brain cell-types fall into two broad categories: neurons and glial cells. These are further subdivided into multiple subtypes with specific functions tightly linked to their morphology. For example, astrocytes and microglia, two types of glial cells, respond very differently to brain inflammation: astrocytes increase in size and their morphology becomes more complex, whereas microglia become rounder and less complex. Gold-standard methods for assessing brain cell morphology are highly invasive. They are rarely applied in humans and cannot be used for repeated assessments over time, which is essential to understanding evolving processes and diseases. Magnetic resonance imaging can non-invasively image brain structure and function, but it cannot currently differentiate cell-type-specific changes. I will build a non-invasive brain cell-type decoder, to extract cellular composition and morphometry for a range of cell subtypes in physiological and pathological conditions, akin to a non-invasive biopsy. To achieve this I propose a novel paradigm built upon diffusion-weighted magnetic resonance spectroscopy (dMRS), a technique that is sensitive to the displacement of intracellular metabolites. I aim to enhance dMRS to achieve cell-subtype specificity and go beyond the glial/neuronal dichotomy. CellPrism’s strategy integrates prior knowledge about cell-types and encompasses the wealth of information available in dMRS in an integrated manner. CellPrism will be validated using causal pharmacological and genetic manipulations in mice. Translation to humans will be conducted at high field, whilst establishing sensitive protocols at accessible clinical fields. Finally, CellPrism will be piloted in patient populations where cellular mechanisms are well described in animal models and post-mortem analyses.

Keywords: non invasive,imaging,mri,diffusion,mrs,brain cell types,brain cell morphology,brain disorders
Toward next-generation X-ray imaging: Pb-free PErovskite Charge Transport engineering (X-PECT)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Physical and Analytical Chemical Sciences
Panel description: Analytical chemistry, chemical theory, physical chemistry/chemical physics
Countries involved: Belgium
Call: ERC STARTING GRANTS (ERC-2023-STG, 2023)
Start date: 2024-01-01
End date: 2028-12-31
Duration (months): 60.0
Total project cost (EUR): 2035525.0
EU funding (EUR): 2035525.0
Participants: 1
Project status: SIGNED

X-rays are widely applied in medical diagnostics, security screening and scientific research. The growing demand for X-ray imaging has increased the frequency with which humans are exposed to ionizing X-rays, directly increasing radiation-related health risks. To minimize these health risks, X-PECT aims to rationally design materials that enable more sensitive X-ray detectors, thus allowing the use of lower operational radiation doses. Metal halide perovskite (MHP) semiconductors have emerged as a highly promising material class for sensitive X-ray detection. Besides their easy processing, the popularity of MHPs arises from their outstanding optoelectronic properties, such as strong high-energy X-ray absorption, and efficient charge carrier generation and transport, outperforming current market standards. However, the intrinsic instability and toxicity of popular lead-based MHPs hinders their large-scale application in sustainable X-ray technology. X-PECT aims for a fundamental understanding of the intrinsic strengths and limitations of MHPs as photoactive material for X-ray detection. In this context, X-PECT will address urging scientific hurdles related to toxicity, structural and chemical stability, intrinsic charge carrier transport efficiency, and processing efforts. The ultimate goal of X-PECT is to rationally develop highly sensitive, sustainable lead-free MHPs through micromanaging their electronic structure by composition and dimensionality engineering. Tailoring their functionality will be guided by applying a full arsenal of both established characterization techniques and unique (micro)spectroscopy platforms for the full assessment of the structural and photophysical properties to identify and suppress the factor(s) currently limiting the X-ray sensitivity and stability. Ultimately, selected candidate materials will be processed into a stable, scalable pixelated X-ray demonstrator device with a 20- to 50-fold improved sensitivity and resolution.

Keywords: semiconductor materials synthesis and engineering